-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AD-214 in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AD-214 in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AD-214 in Chronic Kidney Disease (Chronic Renal...
-
Sector Analysis
Tissue Engineered Skin Substitutes Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
Tissue Engineered Skin Substitutes Market Report Overview The tissue-engineered skin substitutes market size is $2.2 billion in 2023. Factors such as the rise in the prevalence of burn injuries and other skin diseases will drive the market growth at a CAGR of more than 3% during 2023-2033. Tissue engineering for wound care management refers to the mechanical and chemical processing of materials to manufacture products that may substitute or replace all or some components that make up normal skin. Acellular...
-
Sector Analysis
Advanced Wound Dressings Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Advanced Wound Dressings Market Report Overview The advanced wound dressings market size was $3.71 billion in 2023. Factors such as the growing number of hospital-acquired infections and the high prevalence of pressure ulcers will drive the market growth at a CAGR of more than 3% during 2023-2033. Wound dressings involve the use of dressing products combined with drug formulations to provide enhanced healing properties. These dressings are majorly used for the treatment of chronic wounds where they provide a moist...
-
Product Insights
Contrast Agents Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Contrast Agents Pipeline Market Report Overview The Contrast Agents pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments ·       Positron Emitting Tomography Contrast Agents ·       Magnetic Resonance Imaging (MRI) Contrast Agents ·       Gadolinium-based MRI Contrast Agents...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NVH-020B in Hemorrhage
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NVH-020B in Hemorrhage report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NVH-020B in Hemorrhage Drug Details: NVH-020B is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CLN-617 in Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CLN-617 in Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CLN-617 in Head And Neck Cancer Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ST-100 in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ST-100 in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ST-100 in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: ST-100...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PTR-01 in Epidermolysis Bullosa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PTR-01 in Epidermolysis Bullosa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PTR-01 in Epidermolysis Bullosa Drug Details:PTR-01 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mesalamine in Eosinophilic Esophagitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mesalamine in Eosinophilic Esophagitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Mesalamine in Eosinophilic EsophagitisDrug Details:Mesalazine (Salofalk, Canasa, Salo) is an aminosalicylate anti-inflammatory agent....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Tiomolibdate Diammonium in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tiomolibdate Diammonium in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Tiomolibdate Diammonium in Triple-Negative Breast Cancer (TNBC)Drug Details:Tiomolybdate (Coprexa)is under...